Literature DB >> 16019210

Synthesis of [18F]SU11248, a new potential PET tracer for imaging cancer tyrosine kinase.

Ji-Quan Wang1, Kathy D Miller, George W Sledge, Qi-Huang Zheng.   

Abstract

N-[2-(Diethylamino)ethyl]-5-[(Z)-(5-[18F]fluoro-2-oxo-1,2-dihydro-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide, a new potential positron emission tomography tracer for imaging cancer tyrosine kinase, has been prepared by the nucleophilic substitution of the nitro-precursor N-[2-(diethylamino)ethyl]-5-[(Z)-(5-nitro-2-oxo-1,2-dihydro-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide with K18F/Kryptofix 2.2.2 followed by a simple chromatography methodology combined solid-phase extraction with high-performance liquid chromatography purification procedures in 15-25% radiochemical yields.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16019210     DOI： 10.1016/j.bmcl.2005.06.038

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN： 0960-894X            Impact factor:   2.823


  8 in total

Review 1.  Targeted therapies in renal cell cancer: recent developments in imaging.

Authors:  Astrid A M van der Veldt; Martijn R Meijerink; Alfons J M van den Eertwegh; Epie Boven
Journal:  Target Oncol       Date:  2010-07-14       Impact factor: 4.493

Review 2.  Recommendations for the clinical and radiological evaluation of response to treatment in metastatic renal cell cancer.

Authors:  Luís León; Roberto García-Figueiras; Roberto García-Figueras; Cristina Suárez; Antonia Arjonilla; Javier Puente; Blanca Vargas; Maria José Méndez Vidal; Carmen Sebastiá
Journal:  Target Oncol       Date:  2013-12-12       Impact factor: 4.493

3.  Synthesis and in vitro evaluation of [18F](R)-FEPAQ: a potential PET ligand for VEGFR2.

Authors:  Jaya Prabhakaran; Victoria Arango; Vattoly J Majo; Norman R Simpson; Suham A Kassir; Mark D Underwood; Hanish Polavarapu; Jeffrey N Bruce; Peter Canoll; J John Mann; J S Dileep Kumar
Journal:  Bioorg Med Chem Lett       Date:  2012-06-07       Impact factor: 2.823

Review 4.  Molecular imaging of targeted therapies with positron emission tomography: the visualization of personalized cancer care.

Authors:  Lemonitsa H Mammatas; Henk M W Verheul; N Harry Hendrikse; Maqsood Yaqub; Adriaan A Lammertsma; C Willemien Menke-van der Houven van Oordt
Journal:  Cell Oncol (Dordr)       Date:  2014-09-24       Impact factor: 6.730

5.  [Importance of PET for surgery of gastrointestinal stromal tumors].

Authors:  U Ronellenfitsch; B Wängler; S Niedermoser; A Dimitrakopoulou-Strauss; P Hohenberger
Journal:  Chirurg       Date:  2014-06       Impact factor: 0.955

Review 6.  PET imaging with radiolabeled antibodies and tyrosine kinase inhibitors: immuno-PET and TKI-PET.

Authors:  Guus A M S van Dongen; Alex J Poot; Danielle J Vugts
Journal:  Tumour Biol       Date:  2012-01-21

Review 7.  Theragnostic imaging using radiolabeled antibodies and tyrosine kinase inhibitors.

Authors:  Mitsuyoshi Yoshimoto; Hiroaki Kurihara; Hirofumi Fujii
Journal:  ScientificWorldJournal       Date:  2015-03-22

Review 8.  Radiolabeled small molecule protein kinase inhibitors for imaging with PET or SPECT.

Authors:  Justin W Hicks; Henry F VanBrocklin; Alan A Wilson; Sylvain Houle; Neil Vasdev
Journal:  Molecules       Date:  2010-11-15       Impact factor: 4.411
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.